If you are taking a GLP-1 medication and experience any of these symptoms for more than 24 hours, check in with your doctor
Additionally, 85%, 89%, and 91% of participants in the 5 mg, 10 mg, and 15 mg tirzepatide groups, respectively, achieved a 5% or more weight reduction, while only 35% of those on placebo did
If you have any concerns about your triglyceride levels or any other aspect of your health while taking semaglutide, discuss it with your healthcare provider
NICE guidance (NG28) recommends considering dose reductions of insulin or sulfonylureas when initiating a GLP-1 receptor agonist to mitigate this risk
We are not required to agree to your request, and we may say no if it would affect your care
The safety of Semaglutide GLP-1 has not been established in pregnant or breastfeeding women